BOLDON, England, January 14 /PRNewswire/ -- IDS is pleased to announce that their new, unique immunoassay Rat/Mouse PINP- the first commercial EIA to allow the specific assessment of type I collagen levels in rodent specimens*, is now available.
The IDS Rat/Mouse P1NP is the first commercial EIA to allow the specific assessment of type I collagen levels in rodent specimens*. The use of this assay will aid the assessment of new osteoporosis drug candidates in pre-clinical studies and is therefore ideal for Pharmaceutical, Clinical and Academic Research Organizations alike.
The IDS Rat/Mouse PINP EIA is very flexible and measures PINP released from collagen synthesis in rats or mice (plasma or serum). The cross-reactivity with human-derived P1NP is not detectable.
The assay is very simple to perform and results are available in under 3 hours. The assay format and quality also allows one operator to perform over 160 tests per day ensuring high sample throughput and precise, sensitive results.
The combination of 8 well microtiter strips and up to 12 months shelf life also makes this kit ideal for academic researchers with low sample throughput providing quicker and more cost-effective results.
The IDS PINP EIA further expands the range what we believe to be the largest range of Bone & Cartilage Immunoassays available globally.
* Additional Information
The generation of type I collagen is a crucial step in bone formation
where type I collagen is the major organic component of bone matrix.
Propeptides are cleaved from both the N- and C-terminal ends of the
procollagen molecule in equimolar concentrations during collagen synthesis.
Thus, the quantification of N-terminal propeptide of type I procollagen
(PINP) provides measurement of collagen synthesis and/or bone formation.
Head of Marketing,
|SOURCE IDS Ltd|
Copyright©2008 PR Newswire.
All rights reserved